Core Viewpoint - The stock of ZhiJie AnKang-B (02617) has surged over 10%, reaching a new high of 78 HKD, driven by its inclusion in the Hong Kong Stock Connect program and the progress of its clinical trials for its core product, Tinengotinib [1] Group 1: Stock Performance - ZhiJie AnKang-B's stock increased by 10.14%, trading at 69.5 HKD with a transaction volume of 32.81 million HKD [1] Group 2: Market Announcement - The Shanghai Stock Exchange and Shenzhen Stock Exchange announced that ZhiJie AnKang has been added to the Hong Kong Stock Connect eligible list, effective from September 8 [1] Group 3: Clinical Development - ZhiJie AnKang has completed the first patient dosing in a Phase II clinical study for its core product, Tinengotinib, in combination with Canfite BioPharma's treatments for advanced hepatocellular carcinoma [1]
港股异动 | 药捷安康-B(02617)涨超10% 股价刷新上市新高 公司获纳入港股通名单